CA3117911A1 - Antibacterial agent against enterobacterium which contains equol as active ingredient - Google Patents
Antibacterial agent against enterobacterium which contains equol as active ingredient Download PDFInfo
- Publication number
- CA3117911A1 CA3117911A1 CA3117911A CA3117911A CA3117911A1 CA 3117911 A1 CA3117911 A1 CA 3117911A1 CA 3117911 A CA3117911 A CA 3117911A CA 3117911 A CA3117911 A CA 3117911A CA 3117911 A1 CA3117911 A1 CA 3117911A1
- Authority
- CA
- Canada
- Prior art keywords
- equol
- clostridioides
- clostridioides difficile
- enterobacterium
- antibacterial agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Provided is an antibacterial drug against an enterobacterium that can cause an infection in a human body, such as Clostridioides difficile. An antibacterial agent against an enterobacterium, which contains equol as an active ingredient.
Description
Description Title of Invention: ANTIBACTERIAL AGENT AGAINST ENTEROBACTERIUM WHICH
CONTAINS EQUOL AS ACTIVE INGREDIENT
Technical Field [0001]
The present invention relates to an antibacterial agent against enterobacteria, in particular Clostridioides difficile.
Background Art
CONTAINS EQUOL AS ACTIVE INGREDIENT
Technical Field [0001]
The present invention relates to an antibacterial agent against enterobacteria, in particular Clostridioides difficile.
Background Art
[0002]
Clostridioides difficile (C. difficile) is a causal bacterium for Clostridioides difficile infection (CDI), which presents as diarrhea and abdominal pain as symptoms and sometimes leads to death. Clostridioides difficile infection is a problematic nosocomial infection (see Non Patent Literature 1).
Clostridioides difficile (C. difficile) is a causal bacterium for Clostridioides difficile infection (CDI), which presents as diarrhea and abdominal pain as symptoms and sometimes leads to death. Clostridioides difficile infection is a problematic nosocomial infection (see Non Patent Literature 1).
[0003]
Antiprotozoal drugs such as metronidazole and antibiotics such as vancomycin are used as an antibacterial drug against Clostridioides difficile (C. difficile) infection, but once Clostridioides difficile forms spores, effects of these antibacterial drugs are disadvantageously decreased.
Antiprotozoal drugs such as metronidazole and antibiotics such as vancomycin are used as an antibacterial drug against Clostridioides difficile (C. difficile) infection, but once Clostridioides difficile forms spores, effects of these antibacterial drugs are disadvantageously decreased.
[0004]
Clostridioides perfringens (C. perfringens) is an indigenous bacterium in humans, and also detected from domestic animals and fishes. Clostridioides perfringens is resistant to heat, and known to be a causal bacterium for food poisoning.
Clostridioides perfringens (C. perfringens) is an indigenous bacterium in humans, and also detected from domestic animals and fishes. Clostridioides perfringens is resistant to heat, and known to be a causal bacterium for food poisoning.
[0005]
Bacteroides fragilis (B. fragilis) is an indigenous bacterium in humans, and there exists a toxic type of the bacterium. Moreover, Bacteroidesfragilis is said to be a cause for colorectal cancer.
Date Recue/Date Received 2021-04-26
Bacteroides fragilis (B. fragilis) is an indigenous bacterium in humans, and there exists a toxic type of the bacterium. Moreover, Bacteroidesfragilis is said to be a cause for colorectal cancer.
Date Recue/Date Received 2021-04-26
[0006]
Equol is a final metabolite in soybeans, and biosynthesized from soy isoflavone by enterobacteria. Equol has a structure similar to that of estrogen, a female hormone, and hence a method for producing soybean-derived equol has been established (see Patent Literature 1).
Equol is used as an active ingredient of supplements useful for reinforcement of bones and so on (see Patent Literature 2).
Citation List Patent Literature
Equol is a final metabolite in soybeans, and biosynthesized from soy isoflavone by enterobacteria. Equol has a structure similar to that of estrogen, a female hormone, and hence a method for producing soybean-derived equol has been established (see Patent Literature 1).
Equol is used as an active ingredient of supplements useful for reinforcement of bones and so on (see Patent Literature 2).
Citation List Patent Literature
[0007]
Patent Literature 1: JP Patent Publication (Kokai) No. 2017-18120A
Patent Literature 2: JP Patent Publication (Kokai) No. 2013-184959A
Non Patent Literature
Patent Literature 1: JP Patent Publication (Kokai) No. 2017-18120A
Patent Literature 2: JP Patent Publication (Kokai) No. 2013-184959A
Non Patent Literature
[0008]
Non Patent Literature 1: Shigeru KAMIYA, MODERN MEDIA, vol. 56 No. 10 2010 [A
Topical Infection] pp. 233-241 Summary of Invention Technical Problem
Non Patent Literature 1: Shigeru KAMIYA, MODERN MEDIA, vol. 56 No. 10 2010 [A
Topical Infection] pp. 233-241 Summary of Invention Technical Problem
[0009]
An object of the present invention is to provide an antibacterial drug for an enterobacterium that causes an infection in humans, such as Clostridioides difficile.
Solution to Problem
An object of the present invention is to provide an antibacterial drug for an enterobacterium that causes an infection in humans, such as Clostridioides difficile.
Solution to Problem
[0010]
The present inventors examined effects of equol synthesized in the intestine of humans on enterobacteria. The results confirmed that equol inhibits the growth of enterobacteria such as Clostridioides difficile in a concentration-dependent manner and further inhibits the sporulation of Clostridioides difficile, and the present inventors found that equol can be used as Date Recue/Date Received 2021-04-26 an antibacterial agent for enterobacteria such as Clostridioides difficile, thus completing the present invention.
The present inventors examined effects of equol synthesized in the intestine of humans on enterobacteria. The results confirmed that equol inhibits the growth of enterobacteria such as Clostridioides difficile in a concentration-dependent manner and further inhibits the sporulation of Clostridioides difficile, and the present inventors found that equol can be used as Date Recue/Date Received 2021-04-26 an antibacterial agent for enterobacteria such as Clostridioides difficile, thus completing the present invention.
[0011]
Specifically, the present invention is as follows.
[1] An antibacterial agent against an enterobacterium, comprising equol as an active ingredient.
[2] The antibacterial agent according to [1], wherein the enterobacterium is selected from the group consisting of Clostridioides difficile, Clostridioides perfringens (C.
perfringens), and Bacteroides fragilis (B. fragins).
[3] The antibacterial agent according to [1] or [2], wherein the antibacterial agent inhibits the growth of Clostridioides difficile and inhibits the sporulation of Clostridioides [4] A preventive or therapeutic agent for Clostridioides difficile infection, comprising the antibacterial agent according to any one of [1] to [3].
[5] A drug for controlling intestinal function comprising equol as an active ingredient.
[6] The drug for controlling intestinal function according to [5], wherein the drug for controlling intestinal function mitigates symptoms or a symptom of diarrhea and/or abdominal pain caused by the enterobacterium.
[7] A preventive and/or therapeutic agent for colorectal cancer, comprising equol as an active ingredient.
Specifically, the present invention is as follows.
[1] An antibacterial agent against an enterobacterium, comprising equol as an active ingredient.
[2] The antibacterial agent according to [1], wherein the enterobacterium is selected from the group consisting of Clostridioides difficile, Clostridioides perfringens (C.
perfringens), and Bacteroides fragilis (B. fragins).
[3] The antibacterial agent according to [1] or [2], wherein the antibacterial agent inhibits the growth of Clostridioides difficile and inhibits the sporulation of Clostridioides [4] A preventive or therapeutic agent for Clostridioides difficile infection, comprising the antibacterial agent according to any one of [1] to [3].
[5] A drug for controlling intestinal function comprising equol as an active ingredient.
[6] The drug for controlling intestinal function according to [5], wherein the drug for controlling intestinal function mitigates symptoms or a symptom of diarrhea and/or abdominal pain caused by the enterobacterium.
[7] A preventive and/or therapeutic agent for colorectal cancer, comprising equol as an active ingredient.
[0012]
The present specification includes contents disclosed in JP Patent Application No. 2018-203055, to which the present application claims priority.
Advantageous Effects of Invention
The present specification includes contents disclosed in JP Patent Application No. 2018-203055, to which the present application claims priority.
Advantageous Effects of Invention
[0013]
Clostridioides difficile exhibits resistance to antibacterial drugs through formation of spores, and causes an infection by secreting a toxin. Moreover, Clostridioides difficile causes nosocomial infection. Equol is capable of inhibiting the growth of Clostridioides difficile in a concentration-dependent manner and inhibiting the sporulation of Clostridioides difficile, and Date Recue/Date Received 2021-04-26 hence can be used as an antibacterial drug for Clostridioides difficile, and can further prevent nosocomial infection due to Clostridioides Brief Description of Drawings
Clostridioides difficile exhibits resistance to antibacterial drugs through formation of spores, and causes an infection by secreting a toxin. Moreover, Clostridioides difficile causes nosocomial infection. Equol is capable of inhibiting the growth of Clostridioides difficile in a concentration-dependent manner and inhibiting the sporulation of Clostridioides difficile, and Date Recue/Date Received 2021-04-26 hence can be used as an antibacterial drug for Clostridioides difficile, and can further prevent nosocomial infection due to Clostridioides Brief Description of Drawings
[0014]
[Figure 11 Figure 1 shows a graph demonstrating the growth inhibitory effect of equol on a Clostridioides difficile 027 strain.
[Figure 21 Figure 2 shows a graph demonstrating the influence of soy isoflavone on the growth of Clostridioides difficile.
[Figure 31 Figure 3 shows graphs demonstrating the growth inhibitory effect of equol on four bacterial strains of Clostridioides difficile.
[Figure 41 Figure 4 shows graphs demonstrating the growth inhibitory effect of equol on other bacterial species.
[Figure 5] Figure 5 shows photographs demonstrating the influence of equol on the form of Clostridioides [Figure 61 Figure 6 shows a graph demonstrating the sporulation inhibitory effect of equol on Clostridioides Description of Embodiments
[Figure 11 Figure 1 shows a graph demonstrating the growth inhibitory effect of equol on a Clostridioides difficile 027 strain.
[Figure 21 Figure 2 shows a graph demonstrating the influence of soy isoflavone on the growth of Clostridioides difficile.
[Figure 31 Figure 3 shows graphs demonstrating the growth inhibitory effect of equol on four bacterial strains of Clostridioides difficile.
[Figure 41 Figure 4 shows graphs demonstrating the growth inhibitory effect of equol on other bacterial species.
[Figure 5] Figure 5 shows photographs demonstrating the influence of equol on the form of Clostridioides [Figure 61 Figure 6 shows a graph demonstrating the sporulation inhibitory effect of equol on Clostridioides Description of Embodiments
[0015]
Hereinafter, the present invention will be described in detail.
Hereinafter, the present invention will be described in detail.
[0016]
The present invention is an antibacterial agent against an enterobacterium, comprising equol (4',7-isoflavandiol) as an active ingredient.
The present invention is an antibacterial agent against an enterobacterium, comprising equol (4',7-isoflavandiol) as an active ingredient.
[0017]
In the present invention, "antibacterial" refers not to killing bacteria, but to suppressing or inhibiting the growth and proliferation of bacteria, and thus differs from "bactericidal" and "sterilizing".
In the present invention, "antibacterial" refers not to killing bacteria, but to suppressing or inhibiting the growth and proliferation of bacteria, and thus differs from "bactericidal" and "sterilizing".
[0018]
Date Recue/Date Received 2021-04-26 Equol is a final metabolite in soybeans, and biosynthesized from soy isoflavone by enterobacteria. The chemical formula of equol is C151-11403, and the structural formula is shown in the following.
Date Recue/Date Received 2021-04-26 Equol is a final metabolite in soybeans, and biosynthesized from soy isoflavone by enterobacteria. The chemical formula of equol is C151-11403, and the structural formula is shown in the following.
[0019]
[Formula 11 4111 =J,,,....
OH
[Formula 11 4111 =J,,,....
OH
[0020]
Some human individuals are capable of synthesizing equol in the intestine and others are not, and the capability depends on the presence or absence of equol-producing bacteria in his or her intestinal bacterial flora.
Some human individuals are capable of synthesizing equol in the intestine and others are not, and the capability depends on the presence or absence of equol-producing bacteria in his or her intestinal bacterial flora.
[0021]
Equol has antibacterial activity against some enterobacteria.
Examples of enterobacteria for which equol has antibacterial activity include Clostridioides difficile (C.
difficile, CD), Clostridioides perfringens (C. perfringens (Clostridium perfringens)), and Bacteroides fragilis (B. fragilis), and equol is effective for Clostridioides difficile among them.
Equol has antibacterial activity against some enterobacteria.
Examples of enterobacteria for which equol has antibacterial activity include Clostridioides difficile (C.
difficile, CD), Clostridioides perfringens (C. perfringens (Clostridium perfringens)), and Bacteroides fragilis (B. fragilis), and equol is effective for Clostridioides difficile among them.
[0022]
Clostridioides difficile is known to cause Clostridioides difficile infection (CDI), a representative nosocomial infection. Clostridioides difficile infection is a gastrointestinal infection which causes enteritis together with symptoms of diarrhea and abdominal pain, and involves fever or leukocytosis in some cases, occasionally leading to death in serious cases.
Clostridioides difficile forms spores, and if Clostridioides difficile or spores thereof are contained in feces from a CDI patient, in particular, if spores of Clostridioides difficile are contained therein, the feces may allow Clostridioides difficile to remain in a hospital Date Recue/Date Received 2021-04-26 environment including toilet facilities, beds, and floors to cause a serious problem of nosocomial infection. Antiprotozoal drugs such as metronidazole and antibiotics such as vancomycin are used as an antibacterial drug against Clostridioides difficile, but once forming spores, Clostridioides difficile exhibits resistance to antibacterial drugs, and effects of these antibacterial drugs are disadvantageously decreased.
Remaining spores germinate, resulting in the recurrence of Clostridioides difficile infection.
Clostridioides difficile is known to cause Clostridioides difficile infection (CDI), a representative nosocomial infection. Clostridioides difficile infection is a gastrointestinal infection which causes enteritis together with symptoms of diarrhea and abdominal pain, and involves fever or leukocytosis in some cases, occasionally leading to death in serious cases.
Clostridioides difficile forms spores, and if Clostridioides difficile or spores thereof are contained in feces from a CDI patient, in particular, if spores of Clostridioides difficile are contained therein, the feces may allow Clostridioides difficile to remain in a hospital Date Recue/Date Received 2021-04-26 environment including toilet facilities, beds, and floors to cause a serious problem of nosocomial infection. Antiprotozoal drugs such as metronidazole and antibiotics such as vancomycin are used as an antibacterial drug against Clostridioides difficile, but once forming spores, Clostridioides difficile exhibits resistance to antibacterial drugs, and effects of these antibacterial drugs are disadvantageously decreased.
Remaining spores germinate, resulting in the recurrence of Clostridioides difficile infection.
[0023]
Clostridioides perfringens (C. perfringens (Clostridium perfringens)), also called Welch bacillus, is present in the intestine of animals including humans, domestic animals, and fishes, and releases the toxin enterotoxin to cause food poisoning. Since being widely distributed in soils, rivers, oceans, and so on, Clostridioides perfringens often contaminates foods and cooking utensils, and the spore form thereof frequently induces food poisoning because of the thermal durability. In addition, Clostridioides perfringens has been reported to be involved in aging, cancer, and so on.
Clostridioides perfringens (C. perfringens (Clostridium perfringens)), also called Welch bacillus, is present in the intestine of animals including humans, domestic animals, and fishes, and releases the toxin enterotoxin to cause food poisoning. Since being widely distributed in soils, rivers, oceans, and so on, Clostridioides perfringens often contaminates foods and cooking utensils, and the spore form thereof frequently induces food poisoning because of the thermal durability. In addition, Clostridioides perfringens has been reported to be involved in aging, cancer, and so on.
[0024]
Bacteroides fragilis (B. fragilis) is an obligate anaerobic Gram-negative bacillus present in the intestine of humans, and does not form a spore. Bacteroides fragilis may cause an infection when it intrudes into blood vessels or the abdominal cavity.
Bacteroides fragilis has been reported to be involved in the onset of colorectal cancer.
Bacteroides fragilis (B. fragilis) is an obligate anaerobic Gram-negative bacillus present in the intestine of humans, and does not form a spore. Bacteroides fragilis may cause an infection when it intrudes into blood vessels or the abdominal cavity.
Bacteroides fragilis has been reported to be involved in the onset of colorectal cancer.
[0025]
Equol inhibits the growth of the above-described enterobacteria, in particular, Clostridioides difficile in a concentration-dependent manner, and further inhibits the sporulation thereof Equol can ameliorate and prevent Clostridioides difficile infection by inhibiting the growth of Clostridioides difficile in the intestine. By inhibiting the growth of Clostridioides difficile in the intestine, equol can prevent Clostridioides difficile infection from propagating through nosocomial infection or the like. Moreover, equol is capable of inhibiting the sporulation of Clostridioides difficile in the intestine, and hence can prevent Clostridioides difficile infection from propagating via spores.
Equol inhibits the growth of the above-described enterobacteria, in particular, Clostridioides difficile in a concentration-dependent manner, and further inhibits the sporulation thereof Equol can ameliorate and prevent Clostridioides difficile infection by inhibiting the growth of Clostridioides difficile in the intestine. By inhibiting the growth of Clostridioides difficile in the intestine, equol can prevent Clostridioides difficile infection from propagating through nosocomial infection or the like. Moreover, equol is capable of inhibiting the sporulation of Clostridioides difficile in the intestine, and hence can prevent Clostridioides difficile infection from propagating via spores.
[0026]
Date Recue/Date Received 2021-04-26 Equol is useful for subjects without equol-producing bacteria in the intestinal bacterial flora and subjects with equol-producing bacteria in the intestinal bacterial flora.
Date Recue/Date Received 2021-04-26 Equol is useful for subjects without equol-producing bacteria in the intestinal bacterial flora and subjects with equol-producing bacteria in the intestinal bacterial flora.
[0027]
Whether equol has antibacterial activity against an enterobacterium or not can be examined by culturing the enterobacterium to reach a certain bacterial cell count, adding equol in different concentrations to the medium, and subsequently culturing to check the influence on the growth. Culture can be suitably performed, for example, under anaerobic conditions at 30 to 40 C.
Whether equol has antibacterial activity against an enterobacterium or not can be examined by culturing the enterobacterium to reach a certain bacterial cell count, adding equol in different concentrations to the medium, and subsequently culturing to check the influence on the growth. Culture can be suitably performed, for example, under anaerobic conditions at 30 to 40 C.
[0028]
Equol is synthesized from daidzin contained in soybeans as a starting material through a pathway of daidzin ¨> daidzein ¨> dihydrodaidzein ¨> equol by the actions of enterobacteria.
Equol can be synthesized by using bacteria involved in these reactions or enzymes extracted from such bacteria. Methods for producing equol are described in JP Patent Publication (Kokai) No. 2017-205117A, JP Patent Publication (Kokai) No. 2017-18120A, JP
Patent Publication (Kokai) No. 2013-188220A, W02009/084603, and so on, and equol can be produced in accordance with any of these descriptions.
Equol is synthesized from daidzin contained in soybeans as a starting material through a pathway of daidzin ¨> daidzein ¨> dihydrodaidzein ¨> equol by the actions of enterobacteria.
Equol can be synthesized by using bacteria involved in these reactions or enzymes extracted from such bacteria. Methods for producing equol are described in JP Patent Publication (Kokai) No. 2017-205117A, JP Patent Publication (Kokai) No. 2017-18120A, JP
Patent Publication (Kokai) No. 2013-188220A, W02009/084603, and so on, and equol can be produced in accordance with any of these descriptions.
[0029]
Equol may be eighter a synthesized product or a product obtained by fermentation. Any material containing daidzein may be used as a material to ferment for a product obtained by fermentation, and the material is, for example, that derived from soybeans and/or soybean hypocotyls. Examples of equol include equol in fermented products such as equol-containing fermented products of soybean hypocotyls, equol-containing fermented products of soybean hypocotyl extract, equol-containing fermented products of soybeans, and equol-containing fermented products of soybean extract.
Equol may be eighter a synthesized product or a product obtained by fermentation. Any material containing daidzein may be used as a material to ferment for a product obtained by fermentation, and the material is, for example, that derived from soybeans and/or soybean hypocotyls. Examples of equol include equol in fermented products such as equol-containing fermented products of soybean hypocotyls, equol-containing fermented products of soybean hypocotyl extract, equol-containing fermented products of soybeans, and equol-containing fermented products of soybean extract.
[0030]
The antibacterial agent against an enterobacterium, comprising equol as an active ingredient according to the present invention can prevent propagation of pollution with Clostridioides Clostridioides perfringens, or Bacteroides fragilis when being applied to facilities and instruments in hospitals, and against Clostridioides difficile, for example, can Date Recue/Date Received 2021-04-26 further prevent the propagation of Clostridioides difficile infection by inhibiting the growth. In this case, equol can be formulated for use into a dosage form, such as a water-dispersible powder, a liquid, an oil solution, a dusting powder, a grain, a sol (a flowable agent), and a gel, containing [tg/mL to 100 g/mL of equol.
The antibacterial agent against an enterobacterium, comprising equol as an active ingredient according to the present invention can prevent propagation of pollution with Clostridioides Clostridioides perfringens, or Bacteroides fragilis when being applied to facilities and instruments in hospitals, and against Clostridioides difficile, for example, can Date Recue/Date Received 2021-04-26 further prevent the propagation of Clostridioides difficile infection by inhibiting the growth. In this case, equol can be formulated for use into a dosage form, such as a water-dispersible powder, a liquid, an oil solution, a dusting powder, a grain, a sol (a flowable agent), and a gel, containing [tg/mL to 100 g/mL of equol.
[0031]
The antibacterial agent against an enterobacterium, comprising equol as an active ingredient according to the present invention can be used as a pharmaceutical composition to administer to a subject infected with Clostridioides difficile, Clostridioides perfringens, or Bacteroides fragilis, and, for example, is a preventive or therapeutic agent for Clostridioides difficile infection.
The antibacterial agent against an enterobacterium, comprising equol as an active ingredient according to the present invention can be used as a pharmaceutical composition to administer to a subject infected with Clostridioides difficile, Clostridioides perfringens, or Bacteroides fragilis, and, for example, is a preventive or therapeutic agent for Clostridioides difficile infection.
[0032]
The pharmaceutical composition comprising equol as an active ingredient can be used as a drug for controlling intestinal function. The drug for controlling intestinal function can be used to mitigate symptoms or a symptom of diarrhea and/or abdominal pain caused by an enterobacterium.
The pharmaceutical composition comprising equol as an active ingredient can be used as a drug for controlling intestinal function. The drug for controlling intestinal function can be used to mitigate symptoms or a symptom of diarrhea and/or abdominal pain caused by an enterobacterium.
[0033]
Further, enterobacteria for which equol has antibacterial activity are known to be associated with the onset of colorectal cancer. Accordingly, the pharmaceutical composition comprising equol as an active ingredient can be used as a preventive and/or therapeutic agent for colorectal cancer.
Further, enterobacteria for which equol has antibacterial activity are known to be associated with the onset of colorectal cancer. Accordingly, the pharmaceutical composition comprising equol as an active ingredient can be used as a preventive and/or therapeutic agent for colorectal cancer.
[0034]
The antibacterial agent and preventive or therapeutic agent may contain a physiologically acceptable carrier or diluting agent. Examples of the carrier include physiological saline, phosphate-buffered saline, glucose solution, and buffered physiological saline. The pharmaceutical composition for prevention or treatment of infections to be used for subjects infected with Clostridioides Clostridioides perfringens, or Bacteroides fragilis can be administered in various forms. For example, the pharmaceutical composition can be administered through oral administration in the form of a tablet, a capsule, a granule, a powder, or a syrup, or through parenteral administration in the form of an injection, an infusion, or a Date Recue/Date Received 2021-04-26 suppository. Although the dose depends on symptoms, age, body weight, and so on, the dose in oral administration for adults is typically approximately 0.01 mg to 1000 mg per day, and this can be provided in one administration or separately in several administrations. In the case of parenteral administration, a dose of approximately 0.01 mg to 1000 mg can be suitably provided in each administration by subcutaneous injection, intramuscular injection, or intravenous injection.
The antibacterial agent and preventive or therapeutic agent may contain a physiologically acceptable carrier or diluting agent. Examples of the carrier include physiological saline, phosphate-buffered saline, glucose solution, and buffered physiological saline. The pharmaceutical composition for prevention or treatment of infections to be used for subjects infected with Clostridioides Clostridioides perfringens, or Bacteroides fragilis can be administered in various forms. For example, the pharmaceutical composition can be administered through oral administration in the form of a tablet, a capsule, a granule, a powder, or a syrup, or through parenteral administration in the form of an injection, an infusion, or a Date Recue/Date Received 2021-04-26 suppository. Although the dose depends on symptoms, age, body weight, and so on, the dose in oral administration for adults is typically approximately 0.01 mg to 1000 mg per day, and this can be provided in one administration or separately in several administrations. In the case of parenteral administration, a dose of approximately 0.01 mg to 1000 mg can be suitably provided in each administration by subcutaneous injection, intramuscular injection, or intravenous injection.
[0035]
The present invention includes food compositions containing equol. Examples of such food compositions include confectioneries (e.g., cookies, biscuits, chocolates, chips, cakes, chewing gums, candies, gummy candies, manju (sweet buns), yokan (sweet bean jellies), puddings, jellies, yogurt, ice creams, sherbets), breads, noodles, rice foods, cereal foods, beverages (e.g., liquids, soft drinks, carbonated beverages, nutritional beverages, powdered beverages, fruit beverages, milk beverages, jelly beverages), soups (powdered, freeze-dried), and miso (fermented soybean paste) soups (powdered, freeze-dried).
The present invention includes food compositions containing equol. Examples of such food compositions include confectioneries (e.g., cookies, biscuits, chocolates, chips, cakes, chewing gums, candies, gummy candies, manju (sweet buns), yokan (sweet bean jellies), puddings, jellies, yogurt, ice creams, sherbets), breads, noodles, rice foods, cereal foods, beverages (e.g., liquids, soft drinks, carbonated beverages, nutritional beverages, powdered beverages, fruit beverages, milk beverages, jelly beverages), soups (powdered, freeze-dried), and miso (fermented soybean paste) soups (powdered, freeze-dried).
[0036]
The food composition encompasses not only normal foods but also functional foods, for example, including health foods, foods with functional claims, foods for specified health uses, and foods with nutrient function claims. Foods for specified health uses are foods that are ingested for a specific health purpose in meals and shows the indication that the health purpose is expected to be achieved by the ingestion. These foods may be provided, for example, with the indication that this is used for controlling intestinal function or that this is used for mitigation of diarrhea or abdominal pain.
The food composition encompasses not only normal foods but also functional foods, for example, including health foods, foods with functional claims, foods for specified health uses, and foods with nutrient function claims. Foods for specified health uses are foods that are ingested for a specific health purpose in meals and shows the indication that the health purpose is expected to be achieved by the ingestion. These foods may be provided, for example, with the indication that this is used for controlling intestinal function or that this is used for mitigation of diarrhea or abdominal pain.
[0037]
With the food composition according to the present invention, for example, preferably 0.1 mg to 30 mg, more preferably 2 mg to 20 mg, even more preferably 3 mg to 10 mg of equol can be provided per ingestion. Examples of the lower limit value of the amount of equol per ingestion include 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg, examples of the upper limit value include 30 mg, 20 mg, 10 mg, 6 mg, and 5 mg, and a preferred range of the amount Date Recue/Date Received 2021-04-26 of equol per ingestion can be represented by a combination of the upper limit value and the lower limit value.
With the food composition according to the present invention, for example, preferably 0.1 mg to 30 mg, more preferably 2 mg to 20 mg, even more preferably 3 mg to 10 mg of equol can be provided per ingestion. Examples of the lower limit value of the amount of equol per ingestion include 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg, examples of the upper limit value include 30 mg, 20 mg, 10 mg, 6 mg, and 5 mg, and a preferred range of the amount Date Recue/Date Received 2021-04-26 of equol per ingestion can be represented by a combination of the upper limit value and the lower limit value.
[0038]
As mentioned above, it is preferable that the amount of equol ingested per day with the food composition according to the present invention be 30 mg or less. The amount of equol ingested per day is preferably 0.1 mg to 30 mg, more preferably 2 mg to 20 mg, and even more preferably 3 mg to 10 mg. Examples of the lower limit value of the amount of equol ingested per day include 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg, examples of the upper limit value include 30 mg, 20 mg, 10 mg, 6 mg, and 5 mg, and a preferred range of the amount of equol ingestible per day can be represented by a combination of the upper limit value and the lower limit value. Equol in an amount ingestible per day may be provided in one ingestion, or provided separately in multiple ingestions (e.g., two, three, four, and five ingestions).
Examples
As mentioned above, it is preferable that the amount of equol ingested per day with the food composition according to the present invention be 30 mg or less. The amount of equol ingested per day is preferably 0.1 mg to 30 mg, more preferably 2 mg to 20 mg, and even more preferably 3 mg to 10 mg. Examples of the lower limit value of the amount of equol ingested per day include 0.2 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 5 mg, examples of the upper limit value include 30 mg, 20 mg, 10 mg, 6 mg, and 5 mg, and a preferred range of the amount of equol ingestible per day can be represented by a combination of the upper limit value and the lower limit value. Equol in an amount ingestible per day may be provided in one ingestion, or provided separately in multiple ingestions (e.g., two, three, four, and five ingestions).
Examples
[0039]
The present invention will be specifically described with reference to Examples below;
however, the present invention is not limited to these Examples.
The present invention will be specifically described with reference to Examples below;
however, the present invention is not limited to these Examples.
[0040]
[Example 11 Growth Inhibition by Equol on Clostridioides difficile (C.
difficile) 027 Strain Clostridioides (NAP1/027 strain) was added to a medium containing equol in a concentration of 100 Kg/mL, 75 Kg/mL, 50 Kg/mL, or 25 l_tg/mL (0 hour), and subsequently cultured to check the influence on the growth for 24 hours after the start of culture. The culture performed was totally under anaerobic conditions at 35 C.
[Example 11 Growth Inhibition by Equol on Clostridioides difficile (C.
difficile) 027 Strain Clostridioides (NAP1/027 strain) was added to a medium containing equol in a concentration of 100 Kg/mL, 75 Kg/mL, 50 Kg/mL, or 25 l_tg/mL (0 hour), and subsequently cultured to check the influence on the growth for 24 hours after the start of culture. The culture performed was totally under anaerobic conditions at 35 C.
[0041]
Because equol dissolved in DMSO was used, a medium with addition only of DMSO
was additionally subjected to measurement as a control.
Because equol dissolved in DMSO was used, a medium with addition only of DMSO
was additionally subjected to measurement as a control.
[0042]
Date Recue/Date Received 2021-04-26 The growth of the bacterium was examined by measuring the absorbance of each medium at 600 nm (0D600).
Date Recue/Date Received 2021-04-26 The growth of the bacterium was examined by measuring the absorbance of each medium at 600 nm (0D600).
[0043]
Figure 1 shows the results. As demonstrated in Figure 1, the growth of Clostridioides difficile in each of the media with addition of equol was slower than that in the control, which suggested inhibition of growth by equol. The growth rate of Clostridioides difficile was lower as the concentration of equol added was higher, and thus the inhibition depended on the concentration of equol.
Figure 1 shows the results. As demonstrated in Figure 1, the growth of Clostridioides difficile in each of the media with addition of equol was slower than that in the control, which suggested inhibition of growth by equol. The growth rate of Clostridioides difficile was lower as the concentration of equol added was higher, and thus the inhibition depended on the concentration of equol.
[0044]
[Example 21 Influence of Soy Isoflavone on Growth of Clostridioides (NAP1/027 Strain).
Equol is a final product generated from daidzin through daidzein and dihydrodaidzein.
Inhibition of the growth of Clostridioides difficile by equol (100 [tg/mL, 50 [tg/mL), daidzein (50 g/mL), and dihydrodaidzein (100 [tg/mL, 50 g/mL) was measured in the same manner as in Example 1.
[Example 21 Influence of Soy Isoflavone on Growth of Clostridioides (NAP1/027 Strain).
Equol is a final product generated from daidzin through daidzein and dihydrodaidzein.
Inhibition of the growth of Clostridioides difficile by equol (100 [tg/mL, 50 [tg/mL), daidzein (50 g/mL), and dihydrodaidzein (100 [tg/mL, 50 g/mL) was measured in the same manner as in Example 1.
[0045]
Figure 2 shows the results. As demonstrated in Figure 2, although no clear difference from the control was found in the media with addition of 50 [tg/mL of daidzein or dihydrodaidzein, the medium with 100 [tg/mL of dihydrodaidzein and the medium with 50 [tg/mL of equol inhibited the growth of Clostridioides difficile to the same degree, and the medium with 100 [tg/mL of equol exhibited an even higher degree of inhibition than them.
Figure 2 shows the results. As demonstrated in Figure 2, although no clear difference from the control was found in the media with addition of 50 [tg/mL of daidzein or dihydrodaidzein, the medium with 100 [tg/mL of dihydrodaidzein and the medium with 50 [tg/mL of equol inhibited the growth of Clostridioides difficile to the same degree, and the medium with 100 [tg/mL of equol exhibited an even higher degree of inhibition than them.
[0046]
[Example 31 Growth Inhibition on Four Bacterial Strains of Clostridioides Whether clinical isolates of Clostridioides difficile other than the 027 strain (TUM12745 strain, TUM12806 strain, and TUM12855 strain) also undergo growth inhibition by equol (100 [tg/mL) was validated in the same manner as in Example 1.
[Example 31 Growth Inhibition on Four Bacterial Strains of Clostridioides Whether clinical isolates of Clostridioides difficile other than the 027 strain (TUM12745 strain, TUM12806 strain, and TUM12855 strain) also undergo growth inhibition by equol (100 [tg/mL) was validated in the same manner as in Example 1.
[0047]
Figure 3 shows the results. As demonstrated in Figure 3, similar inhibition was found for all the bacterial strains used in the experiment.
Date Recue/Date Received 2021-04-26
Figure 3 shows the results. As demonstrated in Figure 3, similar inhibition was found for all the bacterial strains used in the experiment.
Date Recue/Date Received 2021-04-26
[0048]
[Example 41 Growth Inhibition on Other Bacterial Species Whether equol (100 pg/mL) exhibits inhibition against bacteria other than Clostridioides difficile was validated in the same manner as in Example 1.
[Example 41 Growth Inhibition on Other Bacterial Species Whether equol (100 pg/mL) exhibits inhibition against bacteria other than Clostridioides difficile was validated in the same manner as in Example 1.
[0049]
Figure 4 shows the results. As demonstrated in Figure 4, no influence was found for Escherichia coli (E. coli). An influence was observed for Clostridioides perfringens (C.
perfringens (Clostridium perfringens)) and Bacteroides fragilis (B. fragilis).
In particular, completely no proliferation was found for Bacteroides fragilis, and when being transferred into a medium without equol at the end of 52 hours of the test, Bacteroides fragilis formed a colony;
this revealed that only the growth was inhibited, without killing the bacterium.
Figure 4 shows the results. As demonstrated in Figure 4, no influence was found for Escherichia coli (E. coli). An influence was observed for Clostridioides perfringens (C.
perfringens (Clostridium perfringens)) and Bacteroides fragilis (B. fragilis).
In particular, completely no proliferation was found for Bacteroides fragilis, and when being transferred into a medium without equol at the end of 52 hours of the test, Bacteroides fragilis formed a colony;
this revealed that only the growth was inhibited, without killing the bacterium.
[0050]
[Example 51 Influence on Form (Gram Staining) The influence of equol on the form of Clostridioides difficile (NAP1/027 strain) was validated through staining of Clostridioides difficile with Gram staining under the action of equol (100 Kg/mL) in the same manner as in Example 1.
[Example 51 Influence on Form (Gram Staining) The influence of equol on the form of Clostridioides difficile (NAP1/027 strain) was validated through staining of Clostridioides difficile with Gram staining under the action of equol (100 Kg/mL) in the same manner as in Example 1.
[0051]
Figure 5 shows the stained images. Figure 5 shows images of Gram staining after 8-day culture. Cells with addition of 100 g/mL of equol had forms longer and thinner than those of cells in the control.
Figure 5 shows the stained images. Figure 5 shows images of Gram staining after 8-day culture. Cells with addition of 100 g/mL of equol had forms longer and thinner than those of cells in the control.
[0052]
[Example 6] Inhibition of Sporulation To validate the influence of equol (100 pg/mL) on the sporulation of Clostridioides equol was added to a medium in which Clostridioides difficile had grown to a saturated state, and the number of spores formed was counted.
[Example 6] Inhibition of Sporulation To validate the influence of equol (100 pg/mL) on the sporulation of Clostridioides equol was added to a medium in which Clostridioides difficile had grown to a saturated state, and the number of spores formed was counted.
[0053]
Figure 6 shows the results. As demonstrated in Figure 6, numerous spores were present in the control in every day from day 2; by contrast, the medium with addition of equol had few spores.
Date Recue/Date Received 2021-04-26 Industrial Applicability
Figure 6 shows the results. As demonstrated in Figure 6, numerous spores were present in the control in every day from day 2; by contrast, the medium with addition of equol had few spores.
Date Recue/Date Received 2021-04-26 Industrial Applicability
[0054]
The antibacterial agent comprising equol as an active ingredient according to the present invention exhibits antibacterial action against a microorganism selected from the group consisting of Clostridioides difficile, Clostridioides perfringens, and Bacteroides fragilis, and, for example, can prevent or treat Clostridioides difficile infection, and can prevent nosocomial infection due to Clostridioides difficile.
The antibacterial agent comprising equol as an active ingredient according to the present invention exhibits antibacterial action against a microorganism selected from the group consisting of Clostridioides difficile, Clostridioides perfringens, and Bacteroides fragilis, and, for example, can prevent or treat Clostridioides difficile infection, and can prevent nosocomial infection due to Clostridioides difficile.
[0055]
All the publications, patents, and patent applications cited herein are directly incorporated herein by reference.
Date Recue/Date Received 2021-04-26
All the publications, patents, and patent applications cited herein are directly incorporated herein by reference.
Date Recue/Date Received 2021-04-26
Claims (7)
- [Claim 1]
An antibacterial agent against an enterobacterium, comprising equol as an active ingredient. - [Claim 2]
The antibacterial agent according to claim 1, wherein the enterobacterium is selected from the group consisting of Clostridioides difficile, Clostridioides perfringens (C. perfringens), and Bacteroides fragilis (B. ,fragilis). - [Claim 3]
The antibacterial agent according to claim 1 or 2, wherein the antibacterial agent inhibits the growth of Clostridioides difficile and inhibits the sporulation of Clostridioides difficile. - [Claim 4]
A preventive or therapeutic agent for Clostridioides difficile infection, comprising the antibacterial agent according to any one of claims 1 to 3. - [Claim 5]
A drug for controlling intestinal function comprising equol as an active ingredient. - [Claim 6]
The drug for controlling intestinal function according to claim 5, wherein the drug for controlling intestinal function mitigates symptoms or a symptom of diarrhea and/or abdominal pain caused by the enterobacterium. - [Claim 7]
A preventive and/or therapeutic agent for colorectal cancer, comprising equol as an active ingredient.
Date Recue/Date Received 2021-04-26
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018203055 | 2018-10-29 | ||
| JP2018-203055 | 2018-10-29 | ||
| PCT/JP2019/042299 WO2020090789A1 (en) | 2018-10-29 | 2019-10-29 | Antibacterial agent against enterobacterium which contains equol as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3117911A1 true CA3117911A1 (en) | 2020-05-07 |
Family
ID=70462068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3117911A Pending CA3117911A1 (en) | 2018-10-29 | 2019-10-29 | Antibacterial agent against enterobacterium which contains equol as active ingredient |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210379009A1 (en) |
| EP (1) | EP3875084A4 (en) |
| JP (2) | JP7469778B2 (en) |
| KR (1) | KR20210084558A (en) |
| CN (1) | CN112955140B (en) |
| CA (1) | CA3117911A1 (en) |
| TW (1) | TWI812800B (en) |
| WO (1) | WO2020090789A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116077488A (en) * | 2023-02-22 | 2023-05-09 | 西南医科大学 | New medical application of equol in preventing and treating pathogenic fungi and bacterial infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0813940B1 (en) | 2007-06-13 | 2019-02-05 | Otsuka Pharma Co Ltd | production of the food material containing a fermented soybean hypocotyl containing equol and cocoa mass and a food containing such material |
| CN101952417B (en) | 2007-12-27 | 2015-04-29 | 大塚制药株式会社 | Enzyme involved in synthesis of equol |
| JP6009181B2 (en) | 2012-03-09 | 2016-10-19 | 雪印メグミルク株式会社 | Bone strengthening agent |
| JP6590862B2 (en) | 2017-06-05 | 2019-10-16 | 本田技研工業株式会社 | Suspension arm support structure |
-
2019
- 2019-10-29 KR KR1020217015930A patent/KR20210084558A/en not_active Application Discontinuation
- 2019-10-29 CN CN201980071600.8A patent/CN112955140B/en active Active
- 2019-10-29 JP JP2020553923A patent/JP7469778B2/en active Active
- 2019-10-29 EP EP19880084.9A patent/EP3875084A4/en active Pending
- 2019-10-29 US US17/288,397 patent/US20210379009A1/en active Pending
- 2019-10-29 CA CA3117911A patent/CA3117911A1/en active Pending
- 2019-10-29 TW TW108139010A patent/TWI812800B/en active
- 2019-10-29 WO PCT/JP2019/042299 patent/WO2020090789A1/en unknown
-
2024
- 2024-03-28 JP JP2024052837A patent/JP2024074853A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI812800B (en) | 2023-08-21 |
| JP2024074853A (en) | 2024-05-31 |
| EP3875084A1 (en) | 2021-09-08 |
| CN112955140B (en) | 2023-12-29 |
| CN112955140A (en) | 2021-06-11 |
| EP3875084A4 (en) | 2022-08-10 |
| KR20210084558A (en) | 2021-07-07 |
| JP7469778B2 (en) | 2024-04-17 |
| WO2020090789A1 (en) | 2020-05-07 |
| TW202023538A (en) | 2020-07-01 |
| US20210379009A1 (en) | 2021-12-09 |
| JPWO2020090789A1 (en) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2604689B1 (en) | Anti-obesity agent and anti-obesity food | |
| US20220002664A1 (en) | Lactobacillus reuteri lm1071 from breast milk having high safety and intestine adhesive property, and composition comprising the strain or its culture fluid | |
| KR102153080B1 (en) | A novel strain of Lactobacillus salivarius HEM 1047, and composition for improving gut environment comprising the strain or its culture fluid | |
| KR102174095B1 (en) | A novel strain of Enterococcus faecium HEM 200, and composition for improving gut environment comprising the strain or its culture fluid | |
| JP2024074853A (en) | Antibacterial agent against enterobacterium which contains equol as active ingredient | |
| JP6723980B2 (en) | Colitis suppressant | |
| TWI337079B (en) | Compositions comprising oligosaccharides | |
| KR102201517B1 (en) | A novel strain of Lactobacillus acidophilus HEM 960, and composition for improving gut environment comprising the strain or its culture fluid | |
| JP2024015186A (en) | Composition | |
| KR20200018532A (en) | Lactobacillus sp. strain having inhibitory effect against microorganisms causing vaginosis uses thereof | |
| KR102215592B1 (en) | A novel strain of Lactobacillus fermentum HEM 1036, and composition for improving gut environment comprising the strain or its culture fluid | |
| WO2006132223A1 (en) | Anti-hypertensive composition | |
| KR101234582B1 (en) | Composition for α-glucosidase inhibitory activity | |
| KR20200081721A (en) | COMPOSITION FOR PREVENTING OR TREATING OF GASTRO INTESTINAL TRACT DISEASE COMPRISING STRAIN OF Lactobacillus plantarum G72 | |
| KR20150133351A (en) | Antimicrobial composition comprising flavonol and antibiotic | |
| KR102215596B1 (en) | A novel strain of Streptococcus thermophilus HEM 14, and composition for improving gut environment comprising the strain or its culture fluid | |
| KR102227383B1 (en) | A novel strain of Lactobacillus paracasei HEM 272, and composition for improving gut environment comprising the strain or its culture fluid | |
| KR20190102498A (en) | Lactobacillus sp. strain having inhibitory effect against microorganisms causing vaginosis uses thereof | |
| KR102210092B1 (en) | Lactobacillus reuteri MG505 having anticariogenic activities and composition comprising the same | |
| JP3390613B2 (en) | Bifidus factor activity enhancer / stabilizer | |
| JP2009102276A (en) | Antidiabetic agent | |
| KR102559527B1 (en) | Probiotics complex composition with immunomodulatory and immune homeostasis property | |
| KR102227384B1 (en) | A novel strain of Lactobacillus paracasei HEM 948, and composition for improving gut environment comprising the strain or its culture fluid | |
| KR102215595B1 (en) | A novel strain of Lactobacillus gasseri HEM 622, and composition for improving gut environment comprising the strain or its culture fluid | |
| KR102686044B1 (en) | A novel strain of bifidobacterium bifidum hem972, and composition for improving gut environment comprising the strain or its culture fluid |